We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The combination treatment “significantly prolonged overall survival in the first-line treatment of advanced gastric cancer,” the trial’s principal investigator said. Read More
Innovent Biologics said its investigational gastric cancer drug sintilimab plus chemotherapy delivered promising results in a phase 3 trial as a first-line treatment. Read More
Alzheimer’s patients who took dipeptidyl peptidase-4 inhibitors (DPP-4i) for type 1 diabetes had lower levels of brain amyloid beta than both diabetic patients who hadn’t taken the drug, and a control group of amyloid-positive nondiabetic patients. Read More
Expanding its existing Solidarity trial, the World Health Organization (WHO) will test three additional anti-inflammatory drugs as potential treatments for COVID-19. Read More
AstraZeneca (AZ) and Daiichi Sankyo have announced that an interim analysis from a phase 3 trial showed that their antibody-drug conjugate Enhertu (trastuzumab deruxtecan) posted positive progression-free survival relative to trastuzumab emtansine (T-DM1). Read More
A multidrug chemotherapy cocktail featuring Polivy (polatuzumab vedotin) has scored high as a first-line therapy for patients with diffuse large B-cell lymphoma, (DLBCL), according to preliminary information released by Roche subsidiary Genentech. Read More
In a study of 100 patients who were randomized to receive Nexviazyme or another FDA-approved enzyme replacement therapy, the two treatments showed similar efficacy in improving lung function. Read More